S 2720

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461635

CAS#: 146739-86-8

Description: S 2720 is a human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitor quinoxaline.

Chemical Structure

img
S 2720
CAS# 146739-86-8
Instruction

Theoretical Analysis

MedKoo Cat#: 461635
Name: S 2720
CAS#: 146739-86-8
Chemical Formula: C14H15ClN2O2S
Exact Mass: 310.05
Molecular Weight: 310.790
Elemental Analysis: C, 54.10; H, 4.86; Cl, 11.41; N, 9.01; O, 10.30; S, 10.32

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: S 2720; S-2720; S2720;

IUPAC/Chemical Name: prop-1-en-2-yl 7-chloro-2,2-dimethyl-3-thioxo-3,4-dihydroquinoxaline-1(2H)-carboxylate

InChi Key: UNOJVGJCKUQAGH-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H15ClN2O2S/c1-8(2)19-13(18)17-11-7-9(15)5-6-10(11)16-12(20)14(17,3)4/h5-7H,1H2,2-4H3,(H,16,20)

SMILES Code: O=C(N1C(C)(C)C(NC2=C1C=C(Cl)C=C2)=S)OC(C)=C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 310.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Balzarini J, Karlsson A, Meichsner C, Paessens A, Riess G, De Clercq E, Kleim JP. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J Virol. 1994 Dec;68(12):7986-92. PubMed PMID: 7525984; PubMed Central PMCID: PMC237261.

2: Kleim JP, Bender R, Billhardt UM, Meichsner C, Riess G, Rösner M, Winkler I, Paessens A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother. 1993 Aug;37(8):1659-64. PubMed PMID: 7692812; PubMed Central PMCID: PMC188037.

3: Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme AM, Karlsson A, De Clercq E, Kleim JP, Balzarini J. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol. 1997 Nov;71(11):8195-203. PubMed PMID: 9343170; PubMed Central PMCID: PMC192276.

4: Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 1994 May 1;200(2):696-701. PubMed PMID: 7513921.